Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Deferred Taxes (2016 - 2025)

Ligand Pharmaceuticals' Deferred Taxes history spans 15 years, with the latest figure at -$10.6 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 183.29% year-over-year to -$10.6 million; the TTM value through Dec 2025 reached -$22.7 million, down 243.57%, while the annual FY2025 figure was -$22.7 million, 243.57% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$10.6 million at Ligand Pharmaceuticals, up from -$21.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $20.7 million in Q2 2024 and bottomed at -$46.3 million in Q4 2022.
  • The 5-year median for Deferred Taxes is -$606000.0 (2021), against an average of -$1.5 million.
  • The largest YoY upside for Deferred Taxes was 922.71% in 2022 against a maximum downside of 12000.51% in 2022.
  • A 5-year view of Deferred Taxes shows it stood at $389000.0 in 2021, then plummeted by 12000.51% to -$46.3 million in 2022, then soared by 89.34% to -$4.9 million in 2023, then skyrocketed by 357.18% to $12.7 million in 2024, then tumbled by 183.29% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Deferred Taxes are -$10.6 million (Q4 2025), -$21.3 million (Q3 2025), and $325000.0 (Q2 2025).